Baum Hedlund Aristei & Goldman changed its name to Wisner Baum in January 2023.

Cymbalta Withdrawal Lawsuit

Cymbalta® Withdrawal Lawsuits

We are no longer accepting new Cymbalta cases

Cymbalta® (generic name duloxetine) is a serotonin-norepinephrine reuptake inhibitor or SNRI antidepressant that was widely prescribed to treat depression and anxiety in the early 2000’s and still used today. However, consumers and healthcare professionals nationwide were not fully and accurately informed of the frequency, severity, and duration of Cymbalta withdrawal when it first entered the market in 2004.

Drug manufacturer Eli Lilly and Co, through its nationwide marketing strategy, led consumers and healthcare professionals to believe that Cymbalta withdrawal is rare or uncommon, with a withdrawal rate of only 1%. In truth, a significant percentage of Cymbalta users experience serious symptoms of withdrawal – up to 51%, according to double-blind trials of Cymbalta that were entirely conducted and funded by Lilly. Subsequent studies showed that the real rates may be even higher.

Our Los Angeles attorneys at Baum Hedlund Aristei & Goldman have the most experience in antidepressant litigation of any other plaintiffs’ law firm in the country, including for Cymbalta withdrawal lawsuits. Our firm also has the longest track record of handling antidepressant personal injury and wrongful death cases and remains at the forefront of the antidepressant suicide, withdrawal, and birth defect litigation. In fact, we’ve handled over 4,500 cases against the makers of Prozac, Paxil, Zoloft, Effexor, Celexa, Lexapro, and Cymbalta since 1990, and we’ve won over $4 billion over the last 40 years for injury victims and consumers.

We are no longer accepting Cymbalta cases.

Cymbalta Withdrawal Has Severe Consequences and Side Effects

Shortly after Cymbalta was introduced on the market, many people who used Cymbalta reported that they would experience dramatic withdrawal side effects, such as “brain zaps” or electric shock sensations, body zaps, extreme mood swings, agitation, nausea, and dizziness. A Cymbalta withdrawal study by the drug’s manufacturer Eli Lilly and Co (Lilly) confirmed this experience, finding that withdrawing from Cymbalta often produces severe adverse effects that continue for weeks following discontinuation of the drug.

In the study, the Lilly investigators looked at nine previous trials in which patients had been abruptly withdrawn from Cymbalta. Six were short-term (8-9 weeks) studies and three were long-term studies that lasted for at least 30 weeks. In the short term trials, 44.3% of the patients treated with Cymbalta experienced one or more withdrawal effects. In a large trial included in the Cymbalta withdrawal study involving 1,279 patients, 51% experienced withdrawal symptoms.

The most common withdrawal symptoms associated with Cymbalta were:

  • Dizziness
  • Nausea
  • Headache
  • Paresthesia (electric shock sensations in the brain or “brain zaps”)
  • Diarrhea
  • Vomiting
  • Irritability
  • Insomnia
  • Nightmares
  • Hyperhidrosis (excessive sweating)

In spite of knowing about these side effects, Lilly overplayed the efficacy of Cymbalta. Seeking to capture a greater segment of the antidepressant market in 2005, Lilly initiated a direct-to-consumer marketing campaign with the tagline: “Depression hurts. Cymbalta can help.” Cymbalta advertisements bearing this slogan appeared ubiquitously on television, in print, and on the internet. Lilly’s advertising campaign made it appear that Cymbalta not only treated depression, but that it also treated physical pain associated with depression.

Scientists who reviewed the Cymbalta data have since concluded that Lilly’s claims were misleading. For example, in a 2008 article published in Psychotherapy and Psychosomatics, the author concluded that “the marketing of duloxetine as an antidepressant with analgesic properties for people with depression does not appear to be adequately supported.”

How Did Lilly Manipulate Doctors and the Media?

Lilly also augmented its misleading advertising campaigns by engaging in selective and biased publication of its clinical trials of Cymbalta. In a 2008 study published in the New England Journal of Medicine, researchers obtained clinical trials for antidepressants (including Cymbalta) that had been submitted to the FDA and compared them with studies that had been published. The authors found that there was a clear “bias towards the publication of positive results” and that, “according to the published literature, it appeared that 94% of the trials conducted were positive. By contrast, the FDA analysis shows that 51% were positive.”

The authors found that, as a result of such selective publication, the published literature conveyed a misleading impression of Cymbalta’s efficacy, resulting in an apparent effect size that was 33% larger than the effect size derived from the full clinical trial data. Because of all these efforts – including the direct-to-consumer promotional campaigns, misleading presentation of Cymbalta’s efficacy, and failure to adequately warn regarding Cymbalta’s withdrawal and dependency side effects – Cymbalta eventually became a “blockbuster” drug with over $3 billion dollars in annual sales, making it the second-most profitable drug in Lilly’s product line.

Industry Watchdog Issues Damaging Findings About Cymbalta Withdrawal

In October 2012, the Institute for Safe Medication Practices (ISMP), a non-profit healthcare consumer safety watchdog, issued findings from its independent investigation of Cymbalta adverse events found in the FDA Adverse Event Reporting System (FAERS). The ISMP’s investigation uncovered “a signal for serious drug withdrawal symptoms associated with duloxetine (Cymbalta),” and detailed for the public what Lilly already knew: “Withdrawal symptoms were reported in 44-50% of patients abruptly discontinuing duloxetine at the end of clinical studies for depression, and more than half of this total did not resolve within a week or two.”

The ISMP report continued: “[W]e identified a serious breakdown at both the FDA and the manufacturer, Eli Lilly and Company, in providing adequate warnings and instructions about how to manage this common adverse effect.” Additionally, the FDA-approved patient guide for Cymbalta was found to be “materially deficient,” giving no hint of the persistence or severity of symptoms.

It does not address basic questions about withdrawal like:

  • What kind of symptoms are most common?
  • Should patients taper off the dose, and if so, how slowly?
  • What should a patient do if depression or other symptoms recur?
  • Is there a way to tell whether these are withdrawal symptoms or the previous illness returning?

Holding Lilly Accountable for Dangerous Drug Defects

Declassified court documents obtained by Baum Hedlund during the course of our Cymbalta withdrawal litigation confirmed that Lilly was well aware of Cymbalta’s withdrawal risks, that they occur frequently, and can be quite severe. Instead of being upfront about the risk, however, Lilly hid behind a misleading label, making it appear that the risk was rare and symptoms mild.

Over the past 40 years, our Los Angeles litigation team at Baum Hedlund has led the way in fighting back against these kinds of practices at drug manufacturing companies like Lilly, taking on many cases related to Cymbalta withdrawal, antidepressant-related birth defects, and other dangerous examples of negligence. Our team also helped bring about the black box suicidality warning for children and young adults, now on most antidepressant labels, after finding an internal drug company study linking SSRIs to cardio birth defects. We are also consumer advocates who have testified before state and federal governments on numerous occasions in order to improve consumer and product safety, with many of our attorneys serving in leadership positions on 23 Plaintiffs’ Steering Committees, which oversee complex cases in multi-district litigation.

Contact Us Today

No Fees Unless We Win
  • Please enter your first name.
  • Please enter your last name.
  • +1
    Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your email address.
    This isn't a valid email address.
  • Please enter your city.
  • Please make a selection.
  • Please make a selection.
  • Please make a selection.
  • Please enter a message.
  • Pharmaceutical Settlement $105 Million
  • Paxil Pediatric Class Action $63 Million
  • Third-Party Payer Class Action $40 Million
  • Defective Drug Class Action $28 Million
  • Celexa-Lexapro Pediatric Class Action $10 Million
  • Drug Injury $9 Million
  • Best Law Firms 2023
    Best Law Firms 2023

    A ranking in The U.S. News – Best Lawyers® “Best Law Firms” is widely regarded by both client and legal professionals as a significant honor. It is considered the most reliable, unbiased source of legal referrals anywhere.

  • The Truck Safety Coalition
    The Truck Safety Coalition

    Wisner Baum is proud to be a sponsor of The Truck Safety Coalition, a a group of caring individuals dedicated to reducing the number of deaths and injuries caused by truck-related crashes. Our support enables them to help families and save lives.

  • California Powerhouse
    California Powerhouse

    Law360 recognizes law firms that have a strong regional presence, working on important matters within their home state. “[Wisner Baum] possesses a David v. Goliath-sized slingshot while seeking justice for everyday citizens it believes were harmed or killed through corporate wrongdoing.”

  • Elite Trial Lawyers
    Elite Trial Lawyers

    NLJ and American Lawyer Media honor law firms and attorneys as Elite Trial Lawyers for their cutting-edge legal work on behalf of plaintiffs in practice areas ranging from mass torts to securities litigation.

  • Listed in Best Lawyers
    Listed in Best Lawyers

    Best Lawyers is the oldest and most respected peer-review publication in the legal profession. A listing in Best Lawyers is widely regarded by both clients and legal professionals as a significant honor, conferred on a lawyer by his or her peers.

  • AV Top Ranked Law Firm
    AV Top Ranked Law Firm

    Less than one-half of one percent of firms across the nation have achieved this ranking. A firm must have a high percentage of lawyers who have achieved the prestigious AV® Preeminent rating by Martindale-Hubbell®.

  • Verdicts Hall of Fame
    Verdicts Hall of Fame

    The National Law Journal inducted Wisner Baum into the Verdicts Hall of Fame for obtaining the $2 billion landmark verdict in the Roundup cancer case of Pilliod et al. v. Monsanto. The verdict was #1 in California and #2 in the U.S. in 2019 and is #9 in American history.

  • Super Lawyers
    Super Lawyers

    Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high-degree of peer recognition and professional achievement.

  • National Trial Lawyers Top 100
    National Trial Lawyers Top 100

    The National Trial Lawyers Top 100 recognized the law firms of Wisner Baum, the Miller Firm and Audet & Partners with the 2019 Trial Team of the Year award (in the Mass Torts category) for their work in the groundbreaking case of Dewayne “Lee” Johnson v. Monsanto Company.

  • AV Preeminent Peer Review Rated
    AV Preeminent Peer Review Rated

    An AV® rating reflects an attorney who has reached the heights of professional excellence. The rating signifies the highest legal ability, and very high adherence to professional standards of conduct, ethics, reliability, and diligence.

  • Avvo 10.0 Rating
    Avvo 10.0 Rating

    Wisner Baum is proud to have all of its lawyers listed in Avvo, a legal directory connecting people in need of legal services with lawyers and connecting lawyers to lawyers. Eight of our attorneys have earned a 10.0 perfect rating with Avvo.

  • Top Jury Verdict in <br> CA and USA
    Top Jury Verdict in
    CA and USA ranks our $2 billion verdict in Pilliod et al. v. Monsanto as the biggest verdict in California and the second largest verdict in the U.S. in 2019. It is the ninth largest verdict in U.S. history.

  • Lawdragon 500 Leading Plaintiff Consumer Lawyers
    Lawdragon 500 Leading Plaintiff Consumer Lawyers

    Published annually, the Lawdragon 500 Leading Plaintiff Consumer Lawyers list recognizes the “best of the best” in this area of the law through nominations, research, and review by a board of their peers.

  • Product Liability Practice Group of the Year
    Product Liability Practice Group of the Year

    In 2020, Law360 honored the law firms ”behind the litigation wins and major deals that resonated throughout the legal industry.” It recognized our success in several landmark cases.

  • Top Personal Injury Jury Verdict in California
    Top Personal Injury Jury Verdict in California

    In 2018, our $289 million Johnson v. Monsanto verdict was the largest personal injury verdict in California. also ranked it #2 among all verdicts in California and #10 in the nation.

  • Bar Register of Preeminent Lawyers
    Bar Register of Preeminent Lawyers

    The Bar Register is the definitive guide to the most distinguished law firms in America. It includes only those select law practices that have earned the highest rating in the Martindale-Hubbell Law Directory and have been designated by their colleagues as preeminent in their field.


Firm Reviews

What Our Clients Are Saying
  • I Can’t Imagine a Better Law Firm

    “Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.”

    - Best Law Firms Survey
  • They Are About Changing the Systems...

    “Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.”

    - Kim Witczak
  • Top Legal Minds in the Country

    “The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.”

    - From Best Lawyers® Best Law Firms
  • Diligent & Professional Representation

    “Thanks to your efforts I was able to recover from a tragic experience and turn my life around for the best.”

    - W.T.
  • Our Best Interest Was Always Number One on Your List

    “A special thank you to your Spanish-speaking staff for the extra effort put into this case. The language barrier was never a problem, and we are so very thankful to them. Your name holds much respect in our family.”

    - G.C. & C.C